M&A Deal Summary

Alliance Pharma Acquires Denali Medpharma

On November 1, 2023, Alliance Pharma acquired life science company Denali Medpharma

Acquisition Highlights
  • This is Alliance Pharma’s 2nd transaction in the Life Science sector.
  • This is Alliance Pharma’s 1st transaction in China.

M&A Deal Summary
Date 2023-11-01
Target Denali Medpharma
Sector Life Science
Buyer(s) Alliance Pharma
Deal Type Add-on Acquisition

Target

Denali Medpharma

China
Denali Medpharma is a bioanalytical CRO.

Search 197,704 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Alliance Pharma

Malvern, Pennsylvania, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Alliance Pharma is a contract research organization (CRO) that specializes in advanced bioanalytical research services for both small and large molecule drugs, as well as drug metabolism studies to support pharmaceutical and biotechnology companies’ drug discovery and development programs. Alliance Pharma was founded in 2008 and is headquartered in Malvern, Pennsylvania.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 1 of 1
Country (China) 1 of 1
Year (2023) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-17 DDS

Fordham, United Kingdom

DDS’s Bioanalytical solutions include liquid-chromatography mass spectrometry (LC-MS) and immunoassay bioanalysis, to provide data for pharmacokinetics, immunogenicity, pharmacodynamics, and cell-based assays supporting all phases of drug development to GCP and GLP standards.

Buy -
Mergr

Product

Company

Legal